Suzuki Masaru, Asahina Hajime, Konishi Jun, Yamazaki Koichi, Nishimura Masaharu
First Department of Medicine, Hokkaido University School of Medicine, Sapporo.
Intern Med. 2008;47(6):533-6. doi: 10.2169/internalmedicine.47.0737. Epub 2008 Mar 17.
Gefitinib, the epidermal growth factor receptor tyrosine kinase inhibitor, is effective for patients with non-small cell lung cancer. However, a serious adverse effect, interstitial lung disease (ILD), has been reported. The re-administration of gefitinib might be considered when there is no other choice of treatment and a therapeutic effect can be expected; however, there is no published data on the safety of restarting gefitinib after its discontinuation in cases suspected of having gefitinib-induced ILD. We report a case with recurrent gefitinib-induced ILD, which suggests that re-administration of gefitinib should be considered cautiously in patients who have previously developed gefitinib-induced ILD.
表皮生长因子受体酪氨酸激酶抑制剂吉非替尼对非小细胞肺癌患者有效。然而，已报道有严重不良反应——间质性肺病（ILD）。当没有其他治疗选择且有望产生治疗效果时，可考虑重新使用吉非替尼；然而，对于怀疑由吉非替尼引起的ILD患者，在停药后重新开始使用吉非替尼的安全性尚无公开数据。我们报告了一例复发性吉非替尼诱导的ILD病例，这表明对于先前发生过吉非替尼诱导的ILD的患者，重新使用吉非替尼应谨慎考虑。
